Research that is free to access for all investors. Companies commission these providers to write research about them.
Brokers who write research on their corporate clients and make it available through our main bundle offering.
Research that is paid for directly by asset managers. Only accessible to institutional investors permissioned for access.
Event in Progress:
Discover the latest content that has just been published on Research Tree
Arkema’s FY guidance looked broadly the same between the Q2 and Q3. The range was however condensed to single figures and the wording was changed a bit. This looks like a guidance revision in our view but was so well done that the management was not questioned about this in the conference call. The Q3 figures were a slight beat to consensus at the profitability level (sales: -3.4%; adjusted EBITDA: +2.7%).
Companies: Arkema (AKE:EPA)Arkema SA (AKE:PAR)
AlphaValue
As expected, Arkema reported lower figures compared with the boom, but margins proved resilient reflecting the high share of the specialty chemicals business. However, Intermediates (earmarked for divestment) did better than expected. Interestingly, unlike some of its peers, Arkema did not warn the market about a guidance cut. The company clocked 50% of its guided FY adjusted EBITDA in the first semester confirming our strong view on the stock.
Despite the consensus-beating Q1 profitability, the management was not overly enthusiastic. Interestingly, the Specialty margin fell by less than that of Intermediates, but both parts of the company faced the same triggers for this development. Sales were missed by -1.2% and consensus on the the adjusted EBITDA was beaten by +12.2%.
We had feared that there would be no decent catalysts in 2023 as the change in CEO might not happen this year. There will however be an Investor Day at the end of September, when the management will roll out its new ambitions for the period beyond 2024. The management is very confident that it can reach its 2024 goals as there is only a minor percentage of sales (9%) remaining to be divested. For us, the challenge will rather be the management’s ability to find the right speciality chemicals
The management fully confirmed the FY guidance despite the fact that it was reached after nine months. In the call the management flagged some uncertainties which overhang the performance in the Q4. As destocking seems to be becoming the common denominator in the chemicals industry, we understand why companies are opting for caution. Sales (+6.2%) and adjusted EBITDA (+4.4%) were a clear beat to consensus. The FY consensus currently stands at €2,093m very close to the company’s guidance.
Arkema is now much more fun to cover after a long period of high cyclicality and poor results. For the moment all this is behind us and the management is currently basking in the results of all its hard work. Thing could change rapidly however. Q2 was another consensus-beating quarter (sales: +22.9%; EBITDA: +16.0%), giving the management enough headroom to again raise its guidance after the most recent upgrade in Q1.
Arkema is ‘sailing’ ahead of the cost curve. In our view, this was the main reason for the management to raise the bar. In the call, the management shed some light on the Q2, expecting strong growth at EBITDA level. We are struggling a bit with the low consensus as the beat was substantial (+7.7% to sales, +42.6% to adjusted EBITDA and +52.2% to adjusted EPS). Other companies would have released preliminary figures.
The headline does not imply that Arkema is taking a nap, but another record race should not be expected and the step up is an inorganic one. The 2021 figures were a beat to consensus (sales: +4.2%; adjusted EBITDA: +6.0%). Against the background of the war in Ukraine, we became less optimistic than management.
Arkema was in a position to implement (strong) price increases even in businesses where the company had a ‘tradition’ of suffering from higher raw material prices. We believe availability was also a strong argument. Interestingly, Adhesive Solutions did not benefit as strongly as the other divisions. Q3 figures were above our cautious expectations and beat consensus expectations by +16.4% (top line) and +13.9% (EBITDA).
… to become a speciality chemicals company by 2024, by acquiring something pharma-like. Basically, Arkema plans to acquire the US-based adhesive platforms corralled together at Ashland’s Performance Adhesives business. The charm of the acquisition is that the acquired technologies will be globally rolled out, giving Arkema’s portfolio a broader stance. Management is quite optimistic it can generate substantial synergies including some positive tax effects, which should make the high valuation a
Arkema surfs the chemicals wave well, being carried along by the strong recovery. Supply availability is one side of the coin. On the other, stands cash collection and the company was good at this. Business-wise, the paved path seems to be a well-chosen one. We appreciate the guidance increase, but do not understand that it is based on an unchanged scope after the closing the PMMA divestment. Consensus was beaten by +5.7% (top line) and +21% (adjusted EBITDA).
The top line has already matched the Q1 19 level, but profitability could not fully catch up, despite the optimised business structure, which might be related to the strongly rising raw material prices. Additionally, management managed the organic momentum of the growth well as NWC outflow remained quite stable. Management has become more optimistic after the clear beat in its Q1 guidance. Figures were slightly above our expectations and beat street estimates.
Arkema’s increasing footprint in speciality chemicals helped to protect profitability. Furthermore, management has taken the next steps towards the mid-term target, even in a crisis. By divesting PMMA, its has taken advantage of a special situation, allowing for a decent valuation. Unfortunately, the company still fully consolidates the to-be-divested business showing up our estimates. Consensus was clearly beaten as it still included the PMMA business.
Like other chemicals companies, Arkema had to manoeuvre in challenging times, but the adhesives business was an anchor with its quite resilient business. The other divisions were in rough seas, as expected, giving a mixed picture from a variety of impacts. Intermediates was negatively affected by all factors. The newly-provided guidance looks like a strong commitment. The Q3 figures were a notch stronger than expected, but matched well with the street’s expectations.
Companies: Arkema SA
Like other chemicals, Arkema could not escape from the developments in the customer markets. Nevertheless, the speciality side of the company did quite well despite some meaningful declines in volumes, whereas Intermediates was hit by lower volumes and lower prices. All divisions saw a strong drop in profitability. The divestment proceeds of Functional Polyolefines were a tonic and helped profitability to beat our expectations. Consensus was also beaten.
Research Tree provides access to ongoing research coverage, media content and regulatory news on Arkema SA. We currently have 23 research reports from 3 professional analysts.
Companies: PLL AAL SAV KAV MKA AMC
SP Angel
Companies: 88E MTC TIA DEC ULTP
Cavendish
Ultimate Products’ Q3 trading update reveals that tougher short-term trading trends are now likely to persist into Q4, but the longer-term trends are now more positive due to growing order visibility from its bigger customers. We are downgrading our EPS (Dil. Adj.) forecasts by 22% to 12.5p from 16.0p for FY24E, by 15.3% to 14.8p from 17.4p in FY25E and by 12.6% to 16.6p from 19.0p for FY26E. We reduce our target price to 185p (was 210p) to reflect the new forecasts. Shorter-term issues should r
Companies: Ultimate Products PLC
Ultimate Products announces today that sales revenue fell by 7% in its FY2024 third quarter and is anticipated to remain in negative territory in Q4. As a result, the company believes that EBITDA will now be in the range of £17.5m to £18.5m compared with a current market consensus figure of £21.5m. Given the 17% cut in current year EBITDA expectations it seems prudent to adjust our fair value / share figure by a similar amount. So, we reduce it by 20% from 250p to 200p. However, current sales s
Equity Development
Eden Research has reported its interim results for the 12 months to December 2023. The company generated revenues of £3.2m, slightly ahead of the January trading updated expectation of £3.1m and c15% ahead of our forecast. We note the company generated strong gross profits and an adjusted EBITA ahead of our forecast, both of which we believe were supported by the first commercial sale of Ecovelex. The company closed FY23 with cash slightly below our forecast, which we believe was impacted by the
Companies: Eden Research plc
The focus of Hardman & Co Research is on the nine quoted Infrastructure Investment Companies (IICs) and on the 22 Renewable Energy Infrastructure Funds (REIFs): the stocks analysed are all members of the Association of Investment Companies (AIC). We are updating our publication of January 2023, assessing both the lacklustre share price performances during 2023 and the key issues, including interest rates, inflation and power prices. As a 31-strong group, its combined market capitalisation is no
Companies: AEIT ROOF DGI9 INPP GSF SEIT USFP HICL ORIT BSIF TRIG NESF SEQI HEIT GRP GCP FSFL 3IN AERI PINT RNEW BBGI GSEO DORE TENT GRID CORD HGEN AEET
Hardman & Co
SDI has indicated that a slowdown in the life science / biotech market, and some resultant destocking, is likely to impact its expected FY24 revenue, leading the group to moderate current year guidance for both revenue and adjusted EBITDA. SDI notes that FY24 represents a short-term phenomenon, due to the over-ordering of the past three years caused by inflated Covid demand. However, we remain confident for the long term, given the strength of SDI’s ‘buy and build’ business model, with a number
Companies: SDI Group plc
Progressive Equity Research
Companies: Judges Scientific plc
Shore Capital
Invinity Energy Systems (IES LN) develops Vanadium Flow Batteries (VFBs) for utility-scale grid storage. The Group’s next-generation Mistral VFB technology, jointly developed with Gamesa Electric, launches in H2 2024 to provide grid-scale longer-duration energy storage (LDES) as renewable generation increases globally. To capture this opportunity, the Group has today announced that it has raised £56.0m through a placing at 23p per share. It is now undertaking an Open Offer to raise up to £6.6m a
Companies: Invinity Energy Systems PLC
VSA Capital
Economic and industrial data has started the second quarter on slightly weaker grounds than Q1 as Manufacturing PMI in the UK, Eurozone and US all reported April indexes below March levels. Cracks seem to be appearing as recent drops in new orders and rising input costs are quickly dampening confidence. Inflation did, however, fall MoM across the board with the exception of the US, where volatile energy prices caused a modest MoM increase in the inflation rate.
Companies: TAND AVON RCDO TRI SYM ABDP KETL
Zeus Capital
Companies: ITV RR/ KWS JD/ SENX
We have undertaken a scenario analysis of project funding options for ATOME. Our new backstop valuation based on topco equity funding at the level of the last equity raise gives protection at 64p. A more efficient solution of project sales at FID gives 200p but an even more efficient farm down model gives 252p. Financial close on Villeta this year could be a catalyst for these higher valuations. All options offer strong value at today’s share price and show that ATOME has optionality in financin
Companies: ATOME PLC
Longspur Clean Energy
Invinity’s major equity fundraising is targeting a minimum of £50m with half already committed by the UK Infrastructure Bank (UKIB). A second strategic investment of £3m has been committed by Korean Investment Partners. The raise will see Invinity to net cash generation, with £30m of the raise supporting the company’s scale up ahead of this year’s launch of the next generation Mistral flow battery. The raise will boost the balance sheet, reducing counterparty risk and unlocking sales and bigger
Re-issued to correct for typographical errors.Invinity’s major equity fundraising is targeting a minimum of £56m with £25m already committed by the UK Infrastructure Bank (UKIB). A second strategic investment of £3m has been committed by Korean Investment Partners. The raise will see Invinity to net cash generation, with over £30m of the raise supporting the company’s scale up ahead of this year’s launch of the next generation Mistral flow battery. The raise will boost the balance sheet, reduci
Canaccord Genuity
Share: